Thai Researchers Trace Cancer Links to Common Virus Most Adults Carry
Most adults in Thailand already carry the virus. New research is now clarifying when it becomes dangerous.
The Epstein-Barr virus, known in Thai as khai yaeruman or simply the "kissing disease" virus, infects more than 90% of adults worldwide and remains dormant in the body for life. For most people, it never causes harm. But separate studies published in Thailand between 2024 and 2026 are mapping the circumstances under which the virus reactivates and contributes to oral cancer, head and neck cancers, and diseases of the immune system.
What Thai studies found
Researchers in Thailand identified specific mechanisms linking the virus to cancer progression. A February 2025 study found that a molecule called LINC00944, which is stimulated by the virus, plays a role in how oral cancer cells spread and invade tissue. The finding points to a possible target for future treatment.
A separate study in February 2026 examined genetic and lifestyle factors connected to viral reactivation in the Thai population. The research detected EBV in 36% of normal cheek lining cells, rising to 52% when testing for the LMP-1 protein associated with active infection. The work linked certain genetic mutations, including one called TNF-α (rs1799964), to patients who tested positive for the virus.
The Thailand National Cancer Institute stated in May 2026 that EBV is one of the viruses associated with lymphoma. The institute reminded the public that while the virus is widespread and mostly harmless, a small subset of people with genetic susceptibility, immune weakness, or environmental exposure face higher risks of nasopharyngeal carcinoma — cancer behind the nasal cavity — and certain lymphomas. These cancers are more common in Thai and other Asian populations than in Western ones.
One study in October 2024 found EBV infection in 4.6% of penile cancer patients in Thailand, though researchers noted the link there appears less frequent.
Autoimmune disease connection
Researchers in November 2025 highlighted what they called the "strongest evidence yet" that EBV is a genuine cause of lupus, known in Thai as rok phum phuang or SLE, rather than a harmless passenger virus. The association appears strongest in a minority of patients where the virus does not remain quietly dormant. Scientists found abnormally high levels of infected B-cells in lupus patients and noted that future vaccines against EBV might help prevent the disease.
Thailand has no specific studies published yet linking EBV to multiple sclerosis, though international research in September 2026 suggested that viral reactivation may trigger MS symptoms and that viral proteins can activate MS-risk genes in immune cells before flare-ups occur.
How transmission works
The virus spreads primarily through saliva, which is why it carries the nickname "the kissing disease." It can also transmit through blood and semen. After initial infection, often in childhood, the virus hides in the body and can reactivate later without symptoms, meaning carriers can still infect others.
Those at highest risk for serious complications include people with weakened immune systems — whether from stress, poor nutrition, lack of sleep, HIV infection, chemotherapy, or immunosuppressive medication.
No vaccine yet, limited treatment options
Doctors in Thailand currently have no virus-specific treatment for EBV infection. Management focuses on supporting patients through complications rather than eliminating the virus itself. No licensed vaccine exists, though the recent research linking EBV definitively to autoimmune disease has renewed international interest in developing one.
Broader cancer context
The Thailand National Cancer Institute reports approximately 140,000 new cancer cases per year nationally, with roughly 83,000 deaths. The government has launched the "Thailand Cancer Moonshot 2056" policy, aiming to reduce cancer mortality by 30% over the next 30 years through prevention, screening, and improved treatment.
For most people in Thailand, carrying Epstein-Barr remains a normal fact of life. The new research matters because it clarifies who should be monitored more closely and why — marking a step toward early detection of conditions the virus may help trigger.
